Head-to-head evidence
elecoglipron vs XW003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
elecoglipron
Developed by AstraZeneca
NCT06579092 · Phase 2 · completed
This randomised, triple-blind, placebo-controlled trial in 310 adults living with obesity or overweight reported a 10.5% reduction in body weight on elecoglipron 75 mg against 0.6% on placebo at 26 weeks. Percent weight change is the measure regulators accept as the primary efficacy endpoint in obesity.
Next expected readout: April 2028 · NCT07775404 (registry estimate)
XW003
Developed by Sciwind Biosciences
NCT05813795 · Phase 3 · completed
This randomized, triple-blind, placebo-controlled Phase 3 trial (n=664) in adults with overweight or obesity found that ecnoglutide (XW003) produced significantly greater weight loss than placebo at 40 weeks across all three doses tested, up to 13.2% versus about 0.1% with placebo (p<0.0001 for every dose).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07073417 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: elecoglipron's landscape · XW003's landscape